Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Gujarat Inject (Kerala) Ltd (GUJINJEC) is currently trading at 10.26 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Gujarat Inject Kerala Limited, established in 1991, is primarily engaged in the production of IV fluids, having commenced operations in 2005. The company operates in the pharmaceutical sector, focusing on essential medical products used across hospitals and clinics. Despite limited data availability, Gujarat Inject Kerala Limited's longevity indicates a stable presence in its niche market. While the core focus remains on IV fluids, further data would be crucial to understand any diversification or strategic developments. Historical growth trends and financial performance insights remain sparse, hindering a comprehensive evaluation of the company's market position.
Over the past 52 weeks, Gujarat Inject (Kerala) Ltd has traded between a low of ₹1.90 and a high of ₹14.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Gujarat Inject (Kerala) Ltd has a market capitalization of approximately 155.57. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Gujarat Inject (Kerala) Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 51.86 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 155.57 Cr, Gujarat Inject (Kerala) Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Gujarat Inject (Kerala) Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Gujarat Inject (Kerala) Ltd is 51.86. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The purchase order is valued at approximately ₹144.9 million (₹14.49 crore) and is stated to be exclusive of GST.
FY26 net profit was ₹1.81 crore, up from ₹1.02 crore in FY25, based on audited standalone results for the year ended March 31, 2026.
Gujarat Inject Kerala Limited, established in 1991, is primarily engaged in the production of IV fluids, having commenced operations in 2005.
The company operates in the pharmaceutical sector, focusing on essential medical products used across hospitals and clinics.
Despite limited data availability, Gujarat Inject Kerala Limited's longevity indicates a stable presence in its niche market.
While the core focus remains on IV fluids, further data would be crucial to understand any diversification or strategic developments.
Historical growth trends and financial performance insights remain sparse, hindering a comprehensive evaluation of the company's market position.
Pharmaceuticals & Biotechnology
Pharmaceuticals
156 Cr
Low Risk
51.9
37.7
0.1
13.1
14.30
1.90
Sales CAGR
Profit CAGR
ROE
ROCE
Bearish
4
Neutral
5
Bullish
5
Bearish
31
Neutral
5
Bullish
10
Bearish
27
Neutral
0
Bullish
5
Bearish
4
Neutral
5
Bullish
5
Bearish
4
Neutral
5
Bullish
5
Bearish
27
Neutral
0
Bullish
5
Bearish
27
Neutral
0
Bullish
5
Bearish
27
Neutral
0
Bullish
5
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
31.50 | 171 Cr | 27.79 | 1.19 | 0.00 | 8.93 | 13.60 | 2.10 | ||
6.90 | 164 Cr | 513.63 | 4.69 | 0.00 | 0.90 | 1.13 | 0.84 | ||
218.65 | 161 Cr | 29.98 | 4.29 | 0.00 | 0.00 | 0.00 | 0.00 | ||
259.00 | 160 Cr | 34.12 | 3.72 | 0.00 | 4.47 | 7.31 | 1.55 | ||
10.26 | 156 Cr | 51.86 | 13.14 | 0.00 | 15.34 | 21.17 | 8.18 | ||
114.02 | 151 Cr | 20.87 | 1.84 | 1.26 | 7.64 | 9.18 | 1.93 | ||
132.00 | 145 Cr | 16.18 | 1.52 | 0.00 | 12.38 | 12.15 | 3.93 | ||
| Median: 7 Co. | — | 114.02 | 160 Cr | 29.98 | 3.72 | 0.00 | 7.64 | 9.18 | 1.93 |
